Shenzhen Hyperway Pharmaceutical

Hyperway Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, focused on the discovery and development of innovative small molecule therapeutics. The company specializes in high-prevalence metabolic diseases, including obesity, type 2 diabetes, and NASH/MASH, as well as chronic inflammatory conditions and gout. Their lead programs include HW3323, a URAT1 inhibitor for the treatment of gout, and HW2025, an oral small molecule GLP-1 receptor agonist. Hyperway leverages a proprietary structure-based drug design platform to optimize candidates for superior safety and efficacy profiles. Backed by prominent investors such as Qiming Venture Partners and Matrix Partners China, the company aims to deliver next-generation treatments for global markets.